Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulval and vaginal atrophy." The medication was approved by the FDA in February 2013.
Swamy, Veerabhadra; Bhushan, Kumar Hari; Bhirud, Shekhar Bhaskar; Patil, Dilipkumar Jibhau; Khemnar, Eknath Kundlik. Process for preparation of ospemifene. Assignee Glenmark Pharmaceuticals Limited, India. WO 2016110805. (2016).
Tois, Jan; Pihko, Ainoliisa. Process for the preparation of ospemifene. Assignee Fermion Oy, Finland. WO 2014060640. (2014).
Tois, Jan; Pihko, Ainoliisa; Grumann, Arne. Process for the preparation of ospemifene. Assignee Fermion Oy, Finland. WO 2014060639. (2014).
Li, Ling; Luo, Zhenfu; Zhao, Shiming; Wu, Xuedan; Zhang, Dan; Zhang, Ning. Method for preparing Ospemifene and its intermediate. Assignee Tianjin Institute of Pharmaceutical Research, Peop. Rep. China. CN 103242142. (2013).
